UroGen Pharma Ltd.
URGN | NASDAQ
$43.20
-$0.05 (-0.12%)
At close: Sep 21, 2026, 4:00 PM ET
$44.20
+$1 (+2.31%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -7.34 | -3.60 | -4.23 | -1.85 | -1.92 | -3.05 |
PEG Ratio | -0.94 | 0.22 | 0.16 | 0.54 | 0.12 | -0.15 |
PS Ratio | 10.26 | 5.05 | 5.23 | 3.14 | 4.42 | 33.26 |
PB Ratio | -10.68 | -51.87 | -6.63 | -2.26 | 25.26 | 4.07 |
P/FCF Ratio | -6.92 | -4.70 | -5.65 | -2.30 | -2.48 | -3.66 |
P/OCF Ratio | -6.94 | -4.72 | -5.66 | -2.31 | -2.50 | -3.71 |
OCF/S Ratio | -147.96 | -107.04 | -92.34 | -136.05 | -176.70 | -897.41 |
Debt / Equity Ratio | -1.22 | -14.02 | -1.52 | -1.11 | 0.05 | 0.02 |
Quick Ratio | 3.65 | 5.81 | 5.24 | 5.21 | 4.90 | 5.30 |
Current Ratio | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 | 5.39 |
Asset Turnover | 0.55 | 0.32 | 0.46 | 0.47 | 0.40 | 0.10 |
Interest Coverage | -3.69 | -7.73 | -4.45 | -9.37 | -5.29 | -355.01 |
Return on Equity | 145.53% | 1.44K% | 156.79% | 122.85% | -1.32K% | -133.34% |
Return on Assets | -76.57% | -44.41% | -57.34% | -80.95% | -92.55% | -105.31% |
Return on Invested Capital | -81.06% | -40.37% | -44.55% | -70.76% | -94.79% | -126.02% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% | 91.45% |
Net Profit Margin | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | -1.09K% |
Pretax Profit Margin | -139.74% | -137.22% | -118.87% | -167.86% | -227.66% | -1.06K% |
Operating Profit Margin | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% | -1.07K% |
FCF Margin | -148.22% | -107.37% | -92.57% | -136.45% | -178.27% | -907.71% |
EBITDA Margin | -123.57% | -105.48% | -72.97% | -118.42% | -225.93% | -1.04K% |
Add to Watchlist
Select watchlists to add or remove URGN